Asset profile
peginterferon beta-1a · Plegridy
Biologic (subtype unspecified)
Evidence outlook
Approved: Multiple Sclerosis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
48 competitors in this universe: 3 direct rivals (same mechanism and indication), 4 same-class, 41 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Peginterferon Beta-1a (Plegridy): this drug | Approved | Biologic (subtype unspecified) | Type I interferon receptor, Interferon beta receptor (type I IFN signaling) | ||
| Interferon Beta-1b | Approved | Biologic (subtype unspecified) | Interferon beta receptor (type I IFN signaling), Type I interferon receptor | ||
| Interferon-Beta1 | Approved | Biologic (subtype unspecified) | Type I interferon receptor | ||
| Rebif (interferon Beta 1a) | Approved | Biologic (subtype unspecified) | Interferon beta receptor (type I IFN signaling), Type I interferon receptor | ||
| Anifrolumab | Approved | Monoclonal antibody | Type I interferon receptor, Type I interferon receptor subunit 1 (IFNAR1) | ||
| Interferon Alfa-2b (Intron A) | Approved | — | Type I interferon receptor | ||
| Peginterferon Alfa-2a (Pegasys) | Approved | — | Type I interferon receptor | ||
| Human Serum Albumin / Interferon Alpha2b Fusion Protein | Phase 1/2 | Biologic (subtype unspecified) | Type I interferon receptor | ||
| Aldesleukin (Proleukin) | Approved | Recombinant Cytokine (il-2) | Interleukin-2 receptor (IL-2R) | ||
| Alemtuzumab | Approved | Monoclonal antibody | CD52 | ||
| Bafiertam | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| Cladribine (MAVENCLAD®) | Approved | Small molecule | Adenosine deaminase-resistant purine analog, DNA synthesis machinery in lymphocytes | ||
| Copaxone | Approved | Peptide | Myelin basic protein-mimetic immunomodulation | ||
| Dimethyl Fumarate (Tecfidera) | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| Diroximel Fumarate (Vumerity) | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| DRF | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) |
…and 33 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
May 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.